Stevanato Group S.p.A. Q2 FY26 earnings call STVN

Stevanato Group is strategically focused on the higher-value subsets of the market, particularly biologics and GLP-1 therapies, which are reshaping pharmaceutical product development and commercialization. The company's strategy is anchored in integrated solutions combining device innovation, manufacturing expertise, and supply chain reliability. High-value solutions represented 45% of total revenue in Q2 FY26, driven by a 30% increase in revenue from biologics, the fastest-growing end market. GLP-1 related revenue was approximately 22-23% of total company revenue, with biologics representing 42% of the BDS segment revenue.

The company achieved a significant commercial milestone with regulatory approval in several European countries for a liraglutide-based therapy incorporating its proprietary Alina variable dose pen platform. This approval includes two Alina variants for diabetes and weight management, leveraging the company's integrated capabilities with its world-class cartridge technology. This product, developed over eight years, is manufactured in Germany and is expected to generate double-digit revenue growth in the coming years. Additionally, Stevanato introduced Deora, a novel multi-use fixed-dose pen injector system compatible with prefilled cartridges up to 3ml, addressing the need for strict patient adherence.

The Engineering segment showed continued operational and financial progress, with Q2 results demonstrating positive outcomes from the optimization plan initiated over a year ago. Gross profit margin improved by 540 basis points to 12%, and operating profit margin increased 370 basis points to 2.9%. These improvements were driven by better operating results and a favorable mix from newly secured projects in the Danish operations. The company is making good progress in winning new orders, particularly for visual inspection machines in Europe and Asia, and assembly technology for drug delivery systems in Europe and the United States, despite elongated sales cycles.

Stevanato Group is scaling and executing growth investments in its facilities in Fishers, U.S., and Latina, Italy. In Fishers, initial performance qualification on the first EZ-fill vial line has been completed, with customer validation expected in the near term, and the first device program remains on track for commercial production later this year. In Latina, the syringe ramp-up is ongoing with continued customer validation. The next-generation RTU 400 cartridge line is expected to be completed and installed in the next couple of months, with commercial production anticipated in 2027. The Fishers plant is planned to be fully ramped up by the end of 2028.

The company completed the divestiture of its California-based subsidiary, Balda C. Brewer, which specialized in contract manufacturing services for consumables and point-of-care diagnostic applications. This initiative aligns with Stevanato's long-term goal of optimizing its footprint and accelerating the transition towards more complex, differentiated, and integrated drug delivery systems. The divested subsidiary was expected to generate approximately EUR 30 million in revenue for fiscal year 2026 and the transaction is expected to be accretive on the full-year margins, despite incurring one-time^📎 expenses of EUR 12.2 million related to the sale.

GLP-1 therapies represent a significant and growing market opportunity, with less than 10% patient penetration of a potential 1.5 billion addressable patients globally. Stevanato expects this to be a strong, long-term tailwind, driving double-digit revenue growth for the company in GLP-1 products over the next 5-10 years. Beyond GLP-1s, the broader biologics market is a phenomenal opportunity, with over 9,000 injectable assets in the global drug pipeline, more than 60% of which are biologics. The company is heavily investing in capacity and proprietary devices to maximize its leadership position across various therapeutic areas within biologics.